Convergent Therapeutics, a biotechnology company developing radiopharmaceuticals for cancer, said Wednesday that it has raised $90 million in a Series A financing led by venture investors OrbiMed and RA Capital Management. The funding will help Convergent advance is pipeline of “radioantibodies,” including its lead experimental treatment for prostate cancer.

BioXcel Therapeutics (BTAI) is banking on artificial intelligence to gain a second speedy Food and Drug Administration approval. The possibility could drive BTAI stock higher. The neuroscience industry is riddled with failures. Even in surer areas of drug development, it can take a decade or longer to bring a new medicine to market. But BioXcel did […]

Kyowa Kirin now leads the commercial efforts for Crysvita in 40 countries, continuing its commitment to address the needs of people living with rare diseases. Kyowa Kirin, Inc., a leading global specialty pharmaceutical company, has assumed primary commercial leadership for Crysvita (burosumab injection) in the United States and Canada from Ultragenyx Pharmaceutical, Inc., as per […]